Early Detection and Diagnosis

You have full text access to this OnlineOpen article

Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas

  1. Karolina Partheen1,†,*,
  2. Kristina Levan1,
  3. Lovisa Österberg1,
  4. Ingela Claesson1,
  5. Ghita Fallenius1,
  6. Karin Sundfeldt2,
  7. György Horvath1

Article first published online: 15 AUG 2008

DOI: 10.1002/ijc.23758

Issue

International Journal of Cancer

International Journal of Cancer

Volume 123, Issue 9, pages 2130–2137, 1 November 2008

Additional Information

How to Cite

Partheen, K., Levan, K., Österberg, L., Claesson, I., Fallenius, G., Sundfeldt, K. and Horvath, G. (2008), Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas. Int. J. Cancer, 123: 2130–2137. doi: 10.1002/ijc.23758

Author Information

  1. 1

    Department of Oncology, University of Gothenburg, Gothenburg, Sweden

  2. 2

    Department of Obstetrics and Gynecology, University of Gothenburg, Gothenburg, Sweden

  1. †

    Fax: +46-31-41-72-05.

*Department of Oncology, University of Gothenburg, SE-413 45 Gothenburg, Sweden

Publication History

  1. Issue published online: 25 AUG 2008
  2. Article first published online: 15 AUG 2008
  3. Manuscript Accepted: 20 MAY 2008
  4. Manuscript Received: 28 MAR 2008

Funded by

  • King Gustav V Jubilee Clinic Cancer Research Foundation
  • The Assar Gabrielsson Foundation
  • The Swedish Cancer Foundation

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (369K)

References

  • 1
    Socialstyrelsen TSNBoHaW. Statistics—Health and Diseases 2007. III. Cancer Incidence in Sweden 2005. The Swedish National Board of Health and Welfare, 2007. Available at: http://www.socialstyrelsen.se/NR/rdonlyres/FD7B695E-A55F-41F4-B539-4C63D8199601/7192/2007423.pdf.
  • 2
    Socialstyrelsen TSNBoHaW. Statistics—Health and Diseases 2007. XV. Causes of death, Sweden 2005. The Swedish National Board of Health and Welfare, 2007. Available at: http://www.socialstyrelsen.se/NR/rdonlyres/8747C5D3-700D-4517-8E1F-510FAB8B02C4/9419/20074218.pdf.
  • 3
    Runnebaum IB,Stickeler E. Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol 2001; 127: 73–9.
  • 4
    Heintz AP,Odicino F,Maisonneuve P,Quinn MA,Benedet JL,Creasman WT,Ngan HY,Pecorelli S,Beller U. Carcinoma of the ovary. FIGO 6th Annual Report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006; 95 ( Suppl 1): S161–S192.
  • 5
    Partheen K,Levan K,Osterberg L,Horvath G. Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. Eur J Cancer 2006; 42: 2846–54.
  • 6
    Spentzos D,Levine DA,Ramoni MF,Joseph M,Gu X,Boyd J,Libermann TA,Cannistra SA. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 2004; 22: 4700–10.
  • 7
    Dressman HK,Berchuck A,Chan G,Zhai J,Bild A,Sayer R,Cragun J,Clarke J,Whitaker RS,Li L,Gray J,Marks J, et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007; 25: 517–25.
  • 8
    Vandesompele J,De Preter K,Pattyn F,Poppe B,Van Roy N,De Paepe A,Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.
  • 9
    Zhu Y,Brannstrom M,Janson PO,Sundfeldt K. Differences in expression patterns of the tight junction proteins,claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours. Int J Cancer 2006; 118: 1884–91.
    Direct Link:
  • 10
    Pucci S,Bonanno E,Pichiorri F,Angeloni C,Spagnoli LG. Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 2004; 23: 2298–304.
  • 11
    Jenne DE,Tschopp J. Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated glycoprotein 2, a constituent of rat testis fluid. Proc Natl Acad Sci USA 1989; 86: 7123–7.
  • 12
    de Silva HV,Harmony JA,Stuart WD,Gil CM,Robbins J. Apolipoprotein J: structure and tissue distribution. Biochemistry 1990; 29: 5380–9.
  • 13
    Trougakos IP,Gonos ES. Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol 2002; 34: 1430–48.
  • 14
    Michel D,Chatelain G,North S,Brun G. Stress-induced transcription of the clusterin/apoJ gene. Biochem J 1997; 328 (Part 1): 45–50.
  • 15
    Humphreys DT,Carver JA,Easterbrook-Smith SB,Wilson MR. Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem 1999; 274: 6875–81.
  • 16
    Yang CR,Leskov K,Hosley-Eberlein K,Criswell T,Pink JJ,Kinsella TJ,Boothman DA. Nuclear clusterin/XIP8, an X-ray-induced Ku70-binding protein that signals cell death. Proc Natl Acad Sci USA 2000; 97: 5907–12.
  • 17
    Miyake H,Gleave M,Kamidono S,Hara I. Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Urology 2002; 59: 150–4.
  • 18
    Steinberg J,Oyasu R,Lang S,Sintich S,Rademaker A,Lee C,Kozlowski JM,Sensibar JA. Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res 1997; 3: 1707–11.
  • 19
    Redondo M,Villar E,Torres-Munoz J,Tellez T,Morell M,Petito CK. Overexpression of clusterin in human breast carcinoma. Am J Pathol 2000; 157: 393–9.
  • 20
    Jhala N,Jhala D,Vickers SM,Eltoum I,Batra SK,Manne U,Eloubeidi M,Jones JJ,Grizzle WE. Biomarkers in diagnosis of pancreatic carcinoma in fine-needle aspirates. Am J Clin Pathol 2006; 126: 572–9.
  • 21
    Bettuzzi S,Davalli P,Astancolle S,Carani C,Madeo B,Tampieri A,Corti A. Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens. Cancer Res 2000; 60: 28–34.
  • 22
    Gilks CB,Vanderhyden BC,Zhu S,van de Rijn M,Longacre TA. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol 2005; 96: 684–94.
  • 23
    Xie D,Lau SH,Sham JS,Wu QL,Fang Y,Liang LZ,Che LH,Zeng YX,Guan XY. Up-regulated expression of cytoplasmic clusterin in human ovarian carcinoma. Cancer 2005; 103: 277–83.
    Direct Link:
  • 24
    Albert JM,Gonzalez A,Massion PP,Chen H,Olson SJ,Shyr Y,Diaz R,Lambright ES,Sandler A,Carbone DP,Putnam JB,Jr,Johnson DH, et al. Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 1845–51.
  • 25
    Thiagarajan P,Shapiro SS,Levine E,DeMarco L,Yalcin A. A monoclonal antibody to human platelet glycoprotein IIIa detects a related protein in cultured human endothelial cells. J Clin Invest 1985; 75: 896–901.
  • 26
    Nachman RL,Leung LL. Complex formation of platelet membrane glycoproteins IIb and IIIa with fibrinogen. J Clin Invest 1982; 69: 263–9.
  • 27
    Gardner JM,Hynes RO. Interaction of fibronectin with its receptor on platelets. Cell 1985; 42: 439–48.
  • 28
    Tamkun JW,DeSimone DW,Fonda D,Patel RS,Buck C,Horwitz AF,Hynes RO. Structure of integrin, a glycoprotein involved in the transmembrane linkage between fibronectin and actin. Cell 1986; 46: 271–82.
  • 29
    van der Flier A,Sonnenberg A. Function and interactions of integrins. Cell Tissue Res 2001; 305: 285–98.
  • 30
    Cruet S,Salamanca C,Mitchell GW,Auersperg N. αvβ3 and vitronectin expression by normal ovarian surface epithelial cells: role in cell adhesion and cell proliferation. Gynecol Oncol 1999; 75: 254–60.
  • 31
    Rolli M,Fransvea E,Pilch J,Saven A,Felding-Habermann B. Activated integrin αvβ3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 9482–7.
  • 32
    Felding-Habermann B,Fransvea E,O'Toole TE,Manzuk L,Faha B,Hensler M. Involvement of tumor cell integrin αvβ3 in hematogenous metastasis of human melanoma cells. Clin Exp Metastasis 2002; 19: 427–36.
  • 33
    Carreiras F,Denoux Y,Staedel C,Lehmann M,Sichel F,Gauduchon P. Expression and localization of αv integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma. Gynecol Oncol 1996; 62: 260–7.
  • 34
    Maubant S,Cruet-Hennequart S,Dutoit S,Denoux Y,Crouet H,Henry-Amar M,Gauduchon P. Expression of α V-associated integrin β subunits in epithelial ovarian cancer and its relation to prognosis in patients treated with platinum-based regimens. J Mol Histol 2005; 36: 119–29.
  • 35
    Liapis H,Adler LM,Wick MR,Rader JS. Expression of αvβ3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. Hum Pathol 1997; 28: 443-9.
  • 36
    Adib TR,Henderson S,Perrett C,Hewitt D,Bourmpoulia D,Ledermann J,Boshoff C. Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br J Cancer 2004; 90: 686–92.
  • 37
    Hibbs K,Skubitz KM,Pambuccian SE,Casey RC,Burleson KM,Oegema TR,Jr,Thiele JJ,Grindle SM,Bliss RL,Skubitz AP. Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am J Pathol 2004; 165: 397–414.
  • 38
    Lu KH,Patterson AP,Wang L,Marquez RT,Atkinson EN,Baggerly KA,Ramoth LR,Rosen DG,Liu J,Hellstrom I,Smith D,Hartmann L, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 2004; 10: 3291–300.
  • 39
    Welsh JB,Zarrinkar PP,Sapinoso LM,Kern SG,Behling CA,Monk BJ,Lockhart DJ,Burger RA,Hampton GM. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 2001; 98: 1176–81.
  • 40
    Ikeda H,Lethe B,Lehmann F,van Baren N,Baurain JF,de Smet C,Chambost H,Vitale M,Moretta A,Boon T,Coulie PG. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997; 6: 199–208.
  • 41
    Oberthuer A,Hero B,Spitz R,Berthold F,Fischer M. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res 2004; 10: 4307–13.
  • 42
    Lancaster JM,Dressman HK,Whitaker RS,Havrilesky L,Gray J,Marks JR,Nevins JR,Berchuck A. Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig 2004; 11: 51–9.
  • 43
    Doolan P,Clynes M,Kennedy S,Mehta JP,Crown J,O'Driscoll L. Prevalence and prognostic and predictive relevance of PRAME in breast cancer. Breast Cancer Res Treat 2008; 109: 359–65.
  • 44
    Yin HL. Gelsolin: calcium- and polyphosphoinositide-regulated actin-modulating protein. Bioessays 1987; 7: 176–9.
    Direct Link:
  • 45
    Silacci P,Mazzolai L,Gauci C,Stergiopulos N,Yin HL,Hayoz D. Gelsolin superfamily proteins: key regulators of cellular functions. Cell Mol Life Sci 2004; 61: 2614–23.
  • 46
    Stossel TP. From signal to pseudopod. How cells control cytoplasmic actin assembly. J Biol Chem 1989; 264: 18261–4.
  • 47
    Yu FX,Johnston PA,Sudhof TC,Yin HL. gCap39, a calcium ion- and polyphosphoinositide-regulated actin capping protein. Science 1990; 250: 1413–15.
  • 48
    Renz M,Betz B,Niederacher D,Bender HG,Langowski J. Invasive breast cancer cells exhibit increased mobility of the actin-binding protein CapG. Int J Cancer 2008; 122: 1476–82.
    Direct Link:
  • 49
    Van Ginkel PR,Gee RL,Walker TM,Hu DN,Heizmann CW,Polans AS. The identification and differential expression of calcium-binding proteins associated with ocular melanoma. Biochim Biophys Acta 1998; 1448: 290–7.
  • 50
    Thompson CC,Ashcroft FJ,Patel S,Saraga G,Vimalachandran D,Prime W,Campbell F,Dodson A,Jenkins RE,Lemoine NR,Crnogorac-Jurcevic T,Yin HL, et al. Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility. Gut 2007; 56: 95–106.
  • 51
    De Corte V,Van Impe K,Bruyneel E,Boucherie C,Mareel M,Vandekerckhove J,Gettemans J. Increased importin-β-dependent nuclear import of the actin modulating protein CapG promotes cell invasion. J Cell Sci 2004; 117: 5283–92.
View Full Article (HTML) Get PDF (369K)